Edwards Lifesciences manufactures transcatheter and surgical heart valves, hemodynamic monitoring devices, and related cardiovascular technologies deployed across more than 100 countries. The company pioneered transcatheter aortic valve replacement (TAVR) - a procedural alternative to open-heart surgery - and operates a dedicated Transcatheter Heart Valve business unit. Their product portfolio serves millions of patients annually in hospital and clinical cardiology settings.
The threat surface for medical device manufacturers is distinct. Edwards' infrastructure secures connected devices that monitor and regulate cardiac function, clinical workflows that depend on real-time hemodynamic data, and supply chains for sterile manufacturing and distribution. Compromise scenarios carry direct patient safety implications: device firmware integrity, sensor data authenticity, and procedural software reliability are non-negotiable. The company's global footprint and integration into hospital networks mean security incidents propagate across institutional boundaries.
Edwards operates R&D, manufacturing, and commercial functions across multiple geographies. Clinical evidence generation and regulatory compliance (FDA, CE Mark, and international standards) are embedded in product development. Their security posture must accommodate both legacy device constraints and modern connected-device attack surfaces, while maintaining the audit trails and documentation required for medical device regulation and post-market surveillance.
